When taken orally, the drug usually takes anywhere from one to two hours to be absorbed into the bloodstream. Side effects can occur during that time frame or any time after and include occurrences like dizziness, headaches, drowsiness, nausea, and dry mouth. Said impacts can linger for up to 12 hours after ingesting a dosage but often ebb over shorter durations.
A vital issue to note, however, is that it takes far longer for Cymbalta to begin suppressing the symptoms associated with illnesses it is prescribed to treat. In some cases, users will not notice symptomatic improvement for periods ranging from one to two weeks after beginning treatment. Traces of the drug can remain in a user’s bloodstream for up to two-and-half-days after ingesting their last dose. Ergo, those using the drug over extended durations are more likely to have discernible amounts in their systems even after ceasing ingestion.
Additionally, specific factors can play a role in how long Cymbalta stays in one’s system, including the length of time the user ingested the drug, the specific dosage, an individual’s particular brain and body chemistry, and if ingestion was stopped abruptly.
Other than one’s bloodstream, traces of drugs might also be found in bodily regions like one’s hair and systemic fluids like urine and saliva. In the case of Cymbalta, systemic byproducts of the drug known as metabolites could linger in Hair samples for up to 30 days after a user last ingested the drug. That said, there are no established tests that measure hair’s concentrations of Cymbalta.
Currently, commonly employed urine and saliva tests do not measure Cymbalta concentrations. That said, the drug can occasionally produce false positives for substances like amphetamines. Therefore, should someone prescribed Cymbalta undergo any drug testing for employment or any other purposes, said individual is strongly urged to disclose that they use Cymbalta in advance of the examination.
Scientifically referred to as duloxetine, Cymbalta falls under the category of drugs known as Serotonin and Norepinephrine Reuptake Inhibitors, sometimes abbreviated merely as SNRIs. SNRIs regulate levels of serotonin and norepinephrine, which are two notable brain chemicals responsible for necessary actions like influencing emotions and moods in addition to easing the body’s response to pain.
In therapeutic dosages, Cymbalta has proven effective in treating a variety of mental illnesses and systemic pain disorders, such as major depressive disorders, a host of anxiety problems, pain attributed to diabetic neuropathy and fibromyalgia.
Cymbalta is not considered a controlled substance since it is seldom misused and not believed to precipitate addiction. That said, since the substance influences brain chemistry, it can elicit a variety of side effects. The occurrence and severity of these manifestations may vary depending upon numerous factors, including the condition the drug has been prescribed to treat, the user’s age, weight, general health, the specific dosage, and how long the recipient has been ingesting the said substance.